Results 121 to 130 of about 4,266 (228)

Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects

Indian Journal of Endocrinology and Metabolism
Diabetes mellitus (DM) is a metabolic disorder that leads to the destruction of various tissues including bones. The pathogenesis of osteoporosis (OP) varies in DM due to many specific factors.
Harsh Durgia, Rajan Palui, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Dukhabandhu Naik   +4 more
doaj   +1 more source

Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis

, 2015
Romosozumab inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. This dual effect of romosozumab leads to rapid and substantial increases in areal bone mineral density (aBMD) as measured by dual-energy X-ray ...
Padhi, Desmond, Chang, Sung, Borggrefe, Jan, Campbell, Graeme Michael, Graeff, Christian, Libanati, Cesar, Glüer, Claus Christian, Peña, Jaime Andrés, Kaufman, Allegra   +8 more
core  

Pharmacological Therapy of Osteoporosis: What’s New?

Clinical Interventions in Aging, 2020
Giovanni Iolascon,1 Antimo Moretti,1 Giuseppe Toro,1 Francesca Gimigliano,2 Sara Liguori,1 Marco Paoletta1 1Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Department of
Iolascon G, Moretti A, Toro G, Gimigliano F, Liguori S, Paoletta M   +5 more
doaj  

Incident Vertebral Fractures During Romosozumab Treatment in a Patient With a Pathogenic LRP5 Variant [PDF]

A defect in the canonical Wnt-β-catenin pathway may lead to reduced bone strength and increased fracture risk. Sclerostin is a key inhibitor of this pathway by binding to low-density lipoprotein (LDL) receptor-related protein (LRP)-5/6, thereby reducing ...
van Velsen, Evert, Muradin, Galied, Zillikens, M.C., Wijnen, Mark   +3 more
core   +1 more source

Utilization Of Romosozumab During Covid-19 Pandemic Among U.S. Medicare Beneficiaries

Osteoporosis is increasingly recognized as a major public health issue in the aging U.S. population. Shortly after the licensure of romosozumab, an injectable medication indi-cated for women with postmenopausal osteoporosis at high risk of fracture ...
Liu, Ye
core  

Medical Management of Osteoporosis: Updates and Future Directions

Indian Spine Journal
Osteoporosis, characterized by deterioration of bone microarchitecture, increased bone fragility, and subsequent low-trauma fractures, is the most prevalent bone disease in human beings.
Aasim N. Maldar, Manoj Chadha
doaj   +1 more source

Romosozumab increases bone mineral density in postmenopausal Chinese women with osteoporosis: A randomised phase three study. [PDF]

J Orthop Translat
Zhenlin Z, Qingyun X, Decai C, Aijun C, Yanan H, Mei Z, Xu C, Hua L, Youjia X, Qun C, Huilin Y, Xiaoyan X, Yujie L, Xuan D, Jun J, LingLing G, Theresa RJ, Lars B, Weibo X.   +18 more
europepmc   +1 more source

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

New England Journal of Medicine, 2017
K. Saag, J. Petersen, M. Brandi, A. Karaplis, M. Lorentzon, T. Thomas, J. Maddox, M. Fan, P. Meisner, A. Grauer   +9 more
semanticscholar   +1 more source

A Commentary on "Romosozumab Enhances Implant Stability in Glucocorticoid-Induced Osteoporotic Bone: A Rabbit Model Study". [PDF]

Neurospine
Liu B, Lin H.
europepmc   +1 more source

Use of romosozumab for osteoporosis in β-thalassemia major. [PDF]

JBMR Plus
Ng C, Samad N, Trinh A, Milat F, Wong P.
europepmc   +1 more source